Survival analysis in gastric cancer: a multi-center study among Iranian patients.
Akaike information criterion
Extended cox
Frailty
Gastric cancer
Survival analysis
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
13 Jul 2020
13 Jul 2020
Historique:
received:
23
04
2020
accepted:
06
07
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
19
12
2020
Statut:
epublish
Résumé
Gastric cancer (GC) has been considered as the 5th most common type of cancer and the third leading cause of cancer-associated death worldwide. The aim of this historical cohort study was to evaluate the survival predictors for all patients with GC using the Cox proportional hazards, extended Cox, and gamma-frailty models. This historical cohort study was performed according to documents of 1695 individuals having GC referred to three medical centers in Iran from 2001 to 2018. First, most significant prognostic risk factors on survival were selected, Cox proportional hazards, extended Cox, gamma-frailty models were applied to evaluate the effects of the risk factors, and then these models were compared with the Akaike information criterion. The age of patients, body mass index (BMI), tumor size, type of treatment and grade of the tumor increased the hazard rate (HR) of GC patients in both the Cox and frailty models (P < 0.05). Also, the size of the tumor and BMI were considered as time-varying variables in the extended Cox model. Moreover, the frailty model showed that there is at least an unknown factor, genetic or environmental factors, in the model that is not measured (P < 0.05). Some prognostic factors, including age, tumor size, the grade of the tumor, type of treatment and BMI, were regarded as indispensable predictors in patients of GC. Frailty model revealed that there are unknown or latent factors, genetic and environmental factors, resulting in the biased estimates of the regression coefficients.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer (GC) has been considered as the 5th most common type of cancer and the third leading cause of cancer-associated death worldwide. The aim of this historical cohort study was to evaluate the survival predictors for all patients with GC using the Cox proportional hazards, extended Cox, and gamma-frailty models.
METHODS
METHODS
This historical cohort study was performed according to documents of 1695 individuals having GC referred to three medical centers in Iran from 2001 to 2018. First, most significant prognostic risk factors on survival were selected, Cox proportional hazards, extended Cox, gamma-frailty models were applied to evaluate the effects of the risk factors, and then these models were compared with the Akaike information criterion.
RESULTS
RESULTS
The age of patients, body mass index (BMI), tumor size, type of treatment and grade of the tumor increased the hazard rate (HR) of GC patients in both the Cox and frailty models (P < 0.05). Also, the size of the tumor and BMI were considered as time-varying variables in the extended Cox model. Moreover, the frailty model showed that there is at least an unknown factor, genetic or environmental factors, in the model that is not measured (P < 0.05).
CONCLUSIONS
CONCLUSIONS
Some prognostic factors, including age, tumor size, the grade of the tumor, type of treatment and BMI, were regarded as indispensable predictors in patients of GC. Frailty model revealed that there are unknown or latent factors, genetic and environmental factors, resulting in the biased estimates of the regression coefficients.
Identifiants
pubmed: 32660458
doi: 10.1186/s12893-020-00816-6
pii: 10.1186/s12893-020-00816-6
pmc: PMC7359591
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Références
Gastroenterol Hepatol Bed Bench. 2018 Spring;11(2):110-117
pubmed: 29910851
Environ Sci Pollut Res Int. 2019 Apr;26(11):10487-10495
pubmed: 30806933
J Gastrointest Surg. 2019 Feb;23(2):239-246
pubmed: 30097966
Int J Prev Med. 2019 May 17;10:79
pubmed: 31198514
North Clin Istanb. 2019 Dec 05;7(2):146-152
pubmed: 32259036
J Surg Oncol. 2015 Sep;112(4):387-95
pubmed: 26303645
World J Gastroenterol. 2014 Feb 21;20(7):1635-49
pubmed: 24587643
Stat Med. 2007 Jun 15;26(13):2666-85
pubmed: 17072918
Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):417-20
pubmed: 18990013
Ann Surg Oncol. 2017 Mar;24(3):754-762
pubmed: 27807726
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):412-6
pubmed: 18159979
Gut. 2020 Apr 2;:
pubmed: 32241898
J Res Health Sci. 2012 Dec 13;12(2):127-30
pubmed: 23241526
Clin Transl Oncol. 2020 May;22(5):734-750
pubmed: 31385226
J Gastric Cancer. 2014 Dec;14(4):259-65
pubmed: 25580358
PLoS One. 2016 Jun 16;11(6):e0157401
pubmed: 27309531
Oncotarget. 2017 Mar 21;8(12):20056-20066
pubmed: 28423614
J Res Med Sci. 2019 Oct 25;24:86
pubmed: 31741658
Br J Surg. 2018 Dec;105(13):1807-1815
pubmed: 30132789
World J Gastroenterol. 2004 Dec 1;10(23):3405-8
pubmed: 15526356
J Gastrointest Oncol. 2011 Jun;2(2):77-84
pubmed: 22811834
BMC Gastroenterol. 2011 Oct 01;11:104
pubmed: 21961837
Gastric Cancer. 2018 Jan;21(1):144-154
pubmed: 28417260